Local antitumor effects of intratumoral delivery of rlL-2 loaded sustained-release dextran/PLGA-PLA core/shell microspheres

International Journal of Pharmaceutics

Volumn 450, Issue 1-2, 2013, Pages 235-240

  Zhao, Haiping ^a,c   Wu, Fei ^c   Cai, Yunpeng ^c   Chen, Yinghui ^b   Wei, Liangming ^d   Liu, Zhenguo ^a   Yuan, Weien ^c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d Shanghai Jiao Tong University   (China)

Author keywords

Aqueous aqueous emulsion; dextran PLGA PLA core shell microspheres; Local cancer treatment; rlL 2 loaded sustained release

Indexed keywords

DEXTRAN; MICROSPHERE; POLYLACTIC ACID; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; COLON CARCINOMA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; EMULSION; ENCAPSULATION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DELAYED-ACTION PREPARATIONS; DEXTRANS; INTERLEUKIN-2; LACTIC ACID; MALE; MICE; MICE, INBRED BALB C; MICROSPHERES; POLYGLYCOLIC ACID; POLYMERS; RECOMBINANT PROTEINS;

EID: 84878364859     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.04.051     Document Type: Article

References (31)

1. R. Bannerji, C.D. Arroyo, C. Cordon-Cardo, and E. Gilboa The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity J. Immunol. 152 1994 2324 2332
2. J. Bubenik, J. Simova, and T. Jandlova Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2 Immunol. Lett. 23 1990 287 292
3. Y.H.B. Byeongmoon Jeong, D.S. Lee, and S.W. Kim Biodegradable copolymers as injectable drug-delivery systems Nature 388 1997 860 862
4. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene J. Immunol. 149 1992 3627 3635
5. S. Chouaib, C. Asselin-Paturel, F. Mami-Chouaib, A. Caignard, and J.Y. Blay The host-tumor immune conflict: from immunosuppression to resistance and destruction Immunol. Today 18 1997 493 497
6. S.E. Ettinghausen, E.H. Lipford 3rd, J.J. Mule, and S.A. Rosenberg Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells J. Immunol. 135 1985 3623 3635
7. K. Fu, K. Griebenow, L. Hsieh, A.M. Klibanov, and R. Langer FTIR characterization of the secondary structure of proteins encapsulated within PLGA microspheres J. Control Release 58 1999 357 366
8. B. Gansbacher, K. Zier, B. Daniels, K. Cronin, R. Bannerji, and E. Gilboa Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity J. Exp. Med. 172 1990 1217 1224
9. Y. Geng, W. Yuan, F. Wu, J. Chen, M. He, and T. Jin Formulating erythropoietin-loaded sustained-release PLGA microspheres without protein aggregation J. Control Release 130 2008 259 265
10. G.S. Giancarlo Pizza, D. Menniti, C. De Vinci, and F. Corrado Tumour regression after intralesional injection of interleukin 2 (IL 2) in bladder cancer J. Cancer 34 1984 359 367
11. W.R. Gombotz, and D.K. Pettit Biodegradable polymers for protein and peptide drug delivery Bioconjug. Chem. 6 1995 332 351
12. E.A. Grimm, A. Mazumder, H.Z. Zhang, and S.A. Rosenberg Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes J. Exp. Med. 155 1982 1823 1841
13. E.A. Grimm, R.J. Robb, J.A. Roth, L.M. Neckers, L.B. Lachman, D.J. Wilson, and S.A. Rosenberg Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells J. Exp. Med. 158 1983 1356 1361
14. E. Huland, and H. Huland Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma Cancer Res. 49 1989 5469 5474
15. T. Jin, J. Zhu, F. Wu, W. Yuan, L.L. Geng, and H. Zhu Preparing polymer-based sustained-release systems without exposing proteins to water-oil or water-air interfaces and cross-linking reagents J. Control Release 128 2008 50 59
16. A. Jostel, A. Mukherjee, J. Alenfall, L. Smethurst, and S.M. Shalet A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile Clin. Endocrinol. (Oxf.) 62 2005 623 627
17. R. Langer, and J. Folkman Polymers for the sustained release of proteins and other macromolecules Nature 263 1976 797 800
18. M.T. Lotze, Y.L. Matory, S.E. Ettinghausen, A.A. Rayner, S.O. Sharrow, C.A. Seipp, M.C. Custer, and S.A. Rosenberg In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2 J. Immunol. 135 1985 2865 2875
19. D.M. Pardoll Paracrine cytokine adjuvants in cancer immunotherapy Annu. Rev. Immunol. 13 1995 399 415
20. T. Ren, W. Yuan, H. Zhao, and T. Jin Sustained-release polylactide-co-glycolide microspheres loaded with pre-formulated protein polysaccharide nanoparticles Micro Nano Lett. 6 2011 70 74
21. X. Rong, X. Mo, T. Ren, S. Yang, W. Yuan, J. Dong, Y. Wang, and X. Wang Neuroprotective effect of erythropoietin-loaded composite microspheres on retinal ganglion cells in rats Eur. J. Pharm. Sci. 43 2011 334 342
22. S.A. Rosenberg Progress in human tumour immunology and immunotherapy Nature 411 2001 380 384
23. S.A. Rosenberg, M.T. Lotze, L.M. Muul, A.E. Chang, F.P. Avis, S. Leitman, W.M. Linehan, C.N. Robertson, R.E. Lee, and J.T. Rubin A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone N. Engl. J. Med. 316 1987 889 897
24. M. Rosenstein, I. Yron, Y. Kaufmann, and S.A. Rosenberg Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2 Cancer Res. 44 1984 1946 1953
25. V.R. Sinha, and A. Trehan Biodegradable microspheres for protein delivery J. Control Release 90 2003 261 280
26. G.J. van der Bij, M. Bogels, M.A. Otten, S.J. Oosterling, P.J. Kuppen, S. Meijer, R.H. Beelen, and M. van Egmond Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy J. Hepatol. 53 2010 677 685
27. L.M. Weiner, R. Surana, and S. Wang Monoclonal antibodies: versatile platforms for cancer immunotherapy Nat. Rev. Immunol. 10 2010 317 327
28. F. Wu, and T. Jin Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances AAPS PharmSciTech 9 2008 1218 1229
29. W. Yuan, and Z. Liu Controlled release and preserved bioactivity of proteins from (self-assembled) core-shell double walled microspheres Int. J. Nanomed. 7 2012 257 270
30. W. Yuan, Y. Zhang, F. Wu, H. Li, Y. Cai, Y. Zhang, M. Han, and T. Jin Preparation of protein-loaded sustained-release microspheres via 'solid-in-oil-in-hydrophilic oil-in-ethanol (S/O/hO/E)' emulsification Colloids Surf. B 79 2010 326 333
31. D.B. Zippel, M. Besser, R. Shapira, A. Ben-Nun, D. Goitein, T. Davidson, A.J. Treves, G. Markel, J. Schachter, and M.Z. Papa Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective Exp. Ther. Med. 3 2012 898 902